Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats.

We have studied whether, or not, tissue-specific regulatory mechanisms provide normal 3,5,3'-triiodothyronine (T3) concentrations simultaneously in all tissues of a hypothyroid animal receiving thyroxine (T4), an assumption implicit in the replacement therapy of hypothyroid patients with T4 alone. Thyroidectomized rats were infused with placebo or 1 of 10 T4 doses (0.2-8.0 micrograms per 100 grams of body weight per day). Placebo-infused intact rats served as controls. Plasma and 10 tissues were obtained after 12-13 d of infusion. Plasma thyrotropin and plasma and tissue T4 and T3 were determined by RIA. Iodothyronine-deiodinase activities were assayed using cerebral cortex, liver, and lung. No single dose of T4 was able to restore normal plasma thyrotropin, T4 and T3, as well as T4 and T3 in all tissues, or at least to restore T3 simultaneously in plasma and all tissues. Moreover, in most tissues, the dose of T4 needed to ensure normal T3 levels resulted in supraphysiological T4 concentrations. Notable exceptions were the cortex, brown adipose tissue, and cerebellum, which maintained T3 homeostasis over a wide range of plasma T4 and T3 levels. Deiodinase activities explained some, but not all, of the tissue-specific and dose related changes in tissue T3 concentrations. In conclusion, euthyroidism is not restored in plasma and all tissues of thyroidectomized rats on T4 alone. These results may well be pertinent to patients on T4 replacement therapy.

Congenital hypothyroidism, as studied in rats. Crucial role of maternal thyroxine but not of 3,5,3'-triiodothyronine in the protection of the fetal brain.

To study the protective effects of maternal thyroxine (T4) and 3,5,3'-triiodothyronine (T3) in congenital hypothyroidism, we gave pregnant rats methimazole (MMI), an antithyroid drug that crosses the placenta, and infused them with three different doses of T4 or T3. The concentrations of both T4 and T3 were determined in maternal and fetal plasma and tissues (obtained near term) by specific RIAs. Several thyroid hormone-dependent biological end-points were also measured. MMI treatment resulted in marked fetal T4 and T3 deficiency. Infusion of T4 into the mothers increased both these pools in a dose-dependent fashion. There was a preferential increase of T3 in the fetal brain. Thus, with a T4 dose maintaining maternal euthyroidism, fetal brain T3 reached normal values, although fetal plasma T4 was 40% of normal and plasma TSH was high. The infusion of T3 pool into the mothers increased the total fetal extrathyroidal T3 pool in a dose-dependent fashion. The fetal T4 pools were not increased, however, and this deprived the fetal brain (and possibly the pituitary) of local generation of T3 from T4. As a consequence, fetal brain T3 deficiency was not mitigated even when dams were infused with a toxic dose of T3. The results show that (a) there is a preferential protection of the brain of the hypothyroid fetus from T3 deficiency; (b) maternal T4, but not T3, plays a crucial role in this protection, and (c) any condition which lowers maternal T4 (including treatment with T3) is potentially harmful for the brain of a hypothyroid fetus. Recent confirmation of transplacental passage of T4 in women at term suggests that present results are relevant for human fetuses with impairment of thyroid function. Finding signs of hypothyroidism at birth does not necessarily mean that the brain was unprotected in utero, provided maternal T4 is normal. It is crucial to realize that maintainance of maternal "euthyroidism" is not sufficient, as despite hypothyroxinemia, the mothers may be clinically euthyroid if their T3 levels are normal.

Ontogenesis of thyroid function and interactions with maternal function.

Fetal and neonatal development of thyroid function involves the embryogenesis, differentiation and maturation of the thyroid gland, of the hypothalamic-pituitary-thyroid axis and of the systems controlling thyroid hormone metabolism. We focus here on aspects related to neurodevelopment. Throughout gestation, thyroxine (T4) transferred from the mother, present in embryonic fluids by 4 weeks, protects the fetal brain. Free T4 (FT4) in fetal fluids increases rapidly, approaching adult levels by midgestation, in concentrations that are determined by the maternal serum T4. T3 remains very low throughout pregnancy. In the cerebral cortex T3, generated from T4, reaches adult values by midgestation and is partly bound to specific nuclear receptor isoforms. The iodothyronine deiodinases are important for the spatial and temporal presence of T3 in different fetal brain areas. After onset of fetal thyroid secretion at midgestation, maternal transfer of T4 continues to contribute importantly to fetal serum T4, protecting neurodevelopment until birth. In rats, even a transient period of maternal hypothyroxinemia disrupts neurodevelopment irreversibly, supporting epidemiological evidence for its negative role in human neurodevelopment. The prompt treatment of maternal hypothyroidism or hypothyroxinemia should mitigate negative effects on neurodevelopment. Neurodevelopmental deficits of preterm infants might also result from an untimely interruption of the maternal transfer of T4 [Morreale de Escobar et al: J Clin Endocrinol Metab 2000;85:3975-3987; Best Pract Res Clin Endocrinol Metab 2004;18:225-248; Eur J Endocrinol 2004;151(suppl 3):U25-U37].

Iodothyronine 5'-deiodinase activity in rat brown adipose tissue during development.

Iodothyronine 5'-deiodinase activity in rat brown adipose tissue has a characteristic pattern of developmental changes that is completely different from that of the liver. Fetal brown fat exhibits an extremely high iodothyronine 5'-deiodinase activity that is approx. 10-fold that in adult rats. Even though brown fat iodothyronine 5'-deiodinase activity falls suddenly at birth, there is a new peak in the activity around days 5-7 of life, whereas it remains very low afterwards. Just after birth, brown adipose tissue iodothyronine 5'-deiodinase activity is already capable of stimulation by noradrenaline. The postnatal peak in brown fat iodothyronine 5'-deiodinase correlates with the known increase in the thermogenic activity of the tissue in the neonatal rat, thus reinforcing the suggestion that local 3',3,5-triiodothyronine generation could be an important event related to thermogenesis in brown adipose tissue. However, the high fetal activity was only slightly related to the thermogenic activity of brown fat. Moreover, the increased iodothyronine 5'-deiodinase activity of brown adipose tissue during fetal and neonatal life suggests a substantial contribution by brown fat in the overall extrathyroidal 3',3,5-triiodothyronine production in these physiological periods.

The role of type I and type II 5' deiodinases on hexachlorobenzene-induced alteration of the hormonal thyroid status.

Treatment of male Wistar rats with hexachlorobenzene (HCB) (1000 mg/kg b.w.) for 3-30 days decreases circulating levels of thyroxine (T4) but does not affect triiodothyronine (T3). Time courses were determined for 5' deiodinase type I (5' D-I) activity in thyroid, liver, and kidney and 5' deiodinase type II (5' D-II) activity in brown adipose tissue (BAT) to test the possibility that increased deiodinase activity might contribute to the maintenance of the serum T3 level. Specific 5' D-I activity was increased in the thyroid at 21 days and thereafter. No significant changes were observed in the liver, however, total 5' D-I activity in this tissue was increased at 30 days of treatment as a consequence of liver weight enhancement. HCB decreased kidney 5' D-I activity after 15 days, and BAT 5' D-II activity after 21 days of treatment. Total body 5' D-I activity was significantly increased by 30 days of HCB-treatment. HCB increased the activity of hepatic T4 uridine diphosphoglucuronosyl transferase (UDPGT) in a time-dependent manner, without changes in T3 UDPGT. We propose that increased T4 to T3 conversion in the thyroid and in the greatly enlarged liver may account for the maintenance of serum T3 concentration in hypothyroxinemic HCB-treated rats.

Presence of growth factors-induced type III iodothyronine 5-deiodinase in cultured rat brown adipocytes.

We found low T3 concentrations in rat brown adipocytes differentiated in vitro. This might be due to the high metabolic rate of T3, possibly caused by elevated type III iodothyronine 5-deiodinase activity (5DIII), induced by serum growth factors. We tested the ability of several growth factors to induce 5DIII activity. Epidermal growth factor and basic and acidic fibroblast growth factors produced a strong induction of 5DIII activity (25, 45-, and 50-fold, respectively). This process required gene transcription and de novo protein synthesis. The half-life of 5DIII was approximately 3 h. Heparin was required for full acidic fibroblast growth factor activity. Platelet-derived growth factor, vasopressin, and insulin-like growth factor-I induced lower 5DIII activities (3- to 6-fold). Vasopressin amplified basic fibroblast growth factor and epidermal growth factor inductions when used at submaximal doses. We found a Km of 22.5 nM using T3 as substrate. Although brown adipose tissue has undetectable 5DIII activities in vivo, the present data explain the low T3 concentrations found in cultured rat brown adipocytes and suggest that growth factors, by stimulating 5DIII, may lead to low T3 concentrations and indirectly inhibit the expression of some genes regulated by T3, e.g. the rat uncoupling protein.

Norepinephrine potentiates the mitogenic effect of growth factors in quiescent brown preadipocytes: relationship with uncoupling protein messenger ribonucleic acid expression.

Rat brown preadipocytes cultured in low serum conditions increase DNA synthesis and proliferate in response to serum and a variety of growth factors and hormones. Epidermal growth factor, platelet-derived growth factor, and acidic and basic fibroblast growth factors stimulate DNA synthesis in a dose-dependent manner and induce at least a 5-fold increase in [3H]thymidine incorporation after 40 h of exposure. The physiological activator of brown adipose tissue, norepinephrine, has a low mitogenic effect per se, but increases DNA synthesis stimulation exerted by serum, epidermal growth factor, basic fibroblast growth factor, and the neuropeptide vasopressin. The addition of vasopressin plus norepinephrine greatly potentiates the mitogenic effect of growth factors to levels comparable to the effect of 10% serum. Preadipocytes cultured in the presence of these mitogen combinations (growth factor, vasopressin, and norepinephrine) express a differentiation marker, the uncoupling protein. Thus, our results show 1) that a variety of growth factors and hormones induce DNA synthesis in a synergistic fashion in brown preadipocytes in primary culture; and 2) there is evidence for a role of norepinephrine in the regulation of brown adipocyte proliferation, potentiating the action of serum and mitogens, besides its role in uncoupling protein messenger RNA expression.

Catecholamine stimulation of iodothyronine 5'-deiodinase activity in rat dispersed brown adipocytes.

We describe an in vitro system for evaluating the direct effects of catecholamines on the activity of the type II iodothyronine 5'-deiodinase in dispersed rat brown adipocytes. Incubation with norepinephrine or phenylephrine for 3-4 h causes up to a 5-fold increase in deiodinase activity in these cells. As found in vivo studies, the norepinephrine stimulation is blocked by coincubation with the alpha 1-adrenergic antagonist prazosin. The beta-adrenergic antagonist alprenolol either has no effect or increases stimulation by norepinephrine. These results suggest that beta-adrenergic agonists inhibit the activation or synthesis of the deiodinase in these cells.

The role of 3,3',5'-triiodothyronine in the regulation of type II iodothyronine 5'-deiodinase in the rat cerebral cortex.

Type II iodothyronine 5'-deiodinase (5'D-II) activity is the source of 75-80% of the cerebral cortex T3 content in euthyroid rats. The activity of this enzyme is increased in hypothyroidism and can be quickly suppressed by T4 and rT3 by mechanisms involving neither protein synthesis nor nuclear T3 receptors. We have examined the possibility that endogenous cerebrocortical rT3 levels play a physiological role in the regulation of this enzyme. Thyroidectomized rats were injected with graded doses of [125I]rT3, and cortex 5'D-II activity and rT3 content were determined at various times thereafter. Enzyme activity was reduced as early as 10 min after the injection of 0.75 microgram rT3/100 g BW, and 18 h after 25 micrograms/100 g BW remained 60% suppressed. Regardless of the time after the injection, 5'D-II activity was inversely related to the rT3 content in the cortex; nearly complete suppression was observed at 0.5 ng rT3/g tissue, 50% at 80 pg/g, and 20-30% at 30 pg/g, the euthyroid level. After the infusion of 0.75 microgram rT3/100 g, maximal inhibition occurred at 10 min, before the rT3 content reached maximum levels, and the 5'D-II activity started to recover after the rT3 level fell below 300 pg/g tissue. After increasing doses of T4 administered to thyroidectomized rats, serum and cerebrocortical T4 concentrations increased in a dose-dependent manner, but the increment in the latter was steeper than that in the former. Serum rT3 increments were also proportional to the dose of T4, but cerebrocortical rT3 increased to a greater extent, as evidenced by a 3-fold increment in the cerebrocortical rT3 to T4 ratio. With 1.6 microgram T4/100 g BW, cerebrocortical rT3 reached approximately 100 pg/g, about 3 times the euthyroid level, suggesting that at this T4 dose, the rT3 formed from T4 accounts for part of the inhibition of 5'D-II. With the half-maximal suppressive dose of T4, cortex T4 was about 400 pg/g, but rT3 was negligible. We conclude that: suppression of cortex 5'D-II by rT3 is rapid and requires the presence of rT3 in the tissue (i.e. no long-lived mediators); intracortical rT3 is about 5 times more potent than T4 in suppressing this enzyme; the cortex of rT3-5'D-II suppression relationships suggest that the euthyroid levels of cortex rT3 may be significant in the modulation of 5'D-II.(ABSTRACT TRUNCATED AT 400 WORDS)

Malic enzyme gene expression in differentiating brown adipocytes: regulation by insulin and triiodothyronine.

Primary cultures of brown adipocytes were used to investigate the regulation of malic enzyme (ME) gene expression by insulin and T3. No ME gene expression was detected in undifferentiated preadipocytes. The levels of ME mRNA increased slightly during cell differentiation. Physiological doses of insulin or T3 increased ME gene expression, which reached a maximum after 24 h, on whichever culture day they were added. The effects of insulin and T3 were at the transcriptional level, as measured by run-on assays. Both hormones also increased the stabilization of the transcripts and required ongoing protein synthesis to exert their effects. A comparison of the potencies of insulin and insulin-like growth factor-I and -II (IGF-I and -II) in this system indicated that induction by insulin is mediated via its own receptor. The effects of insulin and T3 were independent of the extracellular glucose concentration, but were additive to that of glucose. Moreover, insulin and T3 act additively to increase ME gene expression, suggesting that they interact either at the transcription level or that of mRNA stabilization.

Thyroid hormones and 5'-deiodinase activity in neonatal undernourished rats.

Undernutrition was induced in rats submitted to food restriction from the fetal stage, and malnutrition was continued after birth until 70 days of life. Body weight was decreased to less than 50%. Plasma T4 and T3 and pituitary TSH content were determined between 8-70 days of life. In control rats, plasma T4 and T3 reached a maximum at 14 and 35 days of life, respectively, and TSH pituitary content at 45 days of life. In undernourished rats, after 8 days of life, plasma T4 and T3 and pituitary TSH content were decreased to about 50% or less, and the pattern of sequential changes observed in control rats was absent or modified. T4 and T3 concentrations were measured in heart, liver, and brain in the fetus (22 days old) and 8, 14, and 23 days after birth, as well as liver and brain 5'-deiodinases (5'D). Hepatic 5'D type I was always decreased in undernourished rats from 8-70 days after birth. Liver and heart T4 and T3 concentrations were decreased in 14-day-old undernourished rats as well as brain T3. Brain 5'D type II was decreased at 8 and 14 days, and total brain 5'D activities at 8 days. These changes occurred during the critical period for brain development (7th to 20th day) during which most processes of myelination take place and T3 brain normal levels are required.

Tyrosine hydroxylase and the conversion of L-thyroxine into 3',3,5-triiodo-L-thyronone in the rat.

We have studied the effects of alpha-methyl-p-tyrosine (alpha-MPT), an inhibitor of tyrosine hydroxylase, on the in vivo conversion of L-T4 (T4) to 3',3,5-triiodo-L-thyronine (T3), and on the biological effectiveness of T4. Thyroidectomized rats were used and were injected daily with T4 maintenance doses. Three different types of experiments were carred out. The first involved isotopic equilibration with 125I-labeled T4 and measurement of urinary 125I excretion. The second series involved the injection of a single dose of [125I]T4, with the amounts of [125I]T3 in different tissues being studied 7 or 20 h later. The third series involved daily treatment for 13 days with T4 and alpha-MPT, at the end of ehich the liver alpha-glycerophosphate dehydrogenase activity was measured as a parameter of the biological effects of the hormone. Though the experimental approaches used clearly disclosed the well known effects of 6-propyl-2-thiouracil, no clear-cut effects of alpha-MPT were observed. It is concluded that alpha-MPT neither inhibits the conversion of T4 to T3 in vivo in rats nor affects the biological potency of a given dose of T4, at least to an extent compararble to that observed when 6-propyl-2-thiouracil is used. Thus, present results do not support the hypothesis that tyrosine hydroxylase is involved in the extrathyroidal deiodination of T4 to T3.

Concentrations of triiodo-L-thyronine in the plasma and tissues of normal rats, as determined by radioimmunoassay: comparison with results obtained by an isotopic equilibrium technique.

The concentrations of T3 (3',3,5-triiodo-L-thyronine) have been determined by RIA in plasma, liver, kidney, heart, muscle, brain, and lungs of normal male rats. The method involves homogenization, addition of a high specific activity labeled T3 tracer, extraction with ethanol, separation by paper chromatography, elution of the labeled T3 spot, evaporation of an aliquot, and assay of its T3 content by a highly sensitive RIA. In order to validate the results thus obtained, they were compared with the T3 concentrations determined for the same samples using an isotopic equilibrium technique. The data obtained by RIA were in close agreement with those derived from the isotopic equilibrium technique, whenever the latter could be applied accurately. The present RIA method permits the determination of T3 in tissues without imposing the well known limitations of the isotopic equilibrium technique. The concentration of T3 was higher in the kidney than in the liver. In kidney, liver, brain, and lung, it was higher than the concentration in plasma. The concentration of T3 in heart was the same as that in plasma. Similarities and differences with respect to data reported by others are discussed.

Thyroid hormone controls the cell-specific expression of the kidney androgen-regulated protein gene in S3 mouse kidney cells.

The kidney androgen-regulated protein (KAP) gene is expressed in epithelial cells of proximal convoluted tubules of mouse kidney. Although TSH proved to be necessary for the constitutive expression of the gene in the outer stripe of the outer medulla, androgens are responsible for expression in cortical segments of the proximal tubules. We have used the congenital thyroid hormone (TH)-deficient hyt/hyt mouse to demonstrate that TH, and not TSH, is responsible for the constitutive expression of the gene in the mouse kidney. Although the androgen-dependent cortical response is partially impaired in hypothyroid mice, the expression can be fully restored after the administration of TH or pharmacological doses of testosterone, suggesting some cooperativity between TH and androgens in promoting cortical KAP gene expression. Results in hyt/hyt mice after treatment with retinoic acid, alone or in combination with TH, demonstrated that this regulator does not have any effect on the regulation of the KAP gene in mouse kidney and that induction of the gene by T3 does not require heterodimerization of TR with retinoic acid-related receptors. By using immunocytochemical analysis and specific antibodies against alpha- and beta-TH receptors we have determined the presence of both types of receptors in all segments of the proximal tubules.

Transcriptional activation of type III inner ring deiodinase by growth factors in cultured rat brown adipocytes.

The activity of the type III inner ring deiodinase (DIII), which converts T4 and T3 to inactive metabolites, is induced by serum and growth factors in primary cultures of rat brown adipocytes. The contribution of pretranslational mechanisms to this increase in DIII activity was examined in the present studies. DIII mRNA is undetectable in differentiated brown adipocytes when cultured in serum-free medium. However, exposure to epidermal growth factor (EGF), acidic or basic fibroblast growth factors (aFGF or bFGF) increase DIII transcript levels. Lesser inductions are found with platelet-derived growth factor, and insulin-like growth factor I has no effect. Maximal induction of DIII mRNA is obtained after 9 h of exposure to EGF, bFGF, or aFGF at a concentration of 10 ng/ml. The increase in DIII mRNA in response to aFGF, bFGF, and EGF requires gene transcription and protein synthesis, as the inductive effect on mRNA is completely blocked by actinomycin D or cycloheximide. The DIII mRNA half-life is 4 h when stimulated with bFGF and increases to 12 h when 10% serum, EGF, or aFGF is present. In conclusion, EGF, aFGF, and bFGF increase DIII mRNA expression in differentiated brown adipocytes. This effect appears to be exerted at the level of both enhanced transcription and mRNA stabilization.

Plasma kinetics, tissue distribution, and cerebrocortical sources of reverse triiodothyronine in the rat.

Studies in vitro have shown that rT3 is a potent and competitive inhibitor of T4 5'-deiodination (5'D). Recent studies in vivo have shown that cerebrocortical (Cx) T4 5'D-type II (5'D-II) activity [propylthiouracil (PTU) insensitive pathway], is reduced by T4 and rT3, the latter being more potent than T3 in Cx 5'D-II suppression. Some other reports had described rT3 production in rat brain as a very active pathway of thyroid hormone metabolism. To examine the possibility that rT3 plays a physiological role in regulating Cx 5'D-II, we have explored rT3 plasma kinetics, plasma to tissue exchange, and uptake by tissues in the rat, as well as the metabolic routes of degradation and the sources of rT3 in cerebral cortex (Cx). Plasma and tissue levels were assessed with tracer [125I]rT3. Two main compartments were defined by plasma disappearance curves in euthyroid rats (K1 = -6.2 h-1 and K2 = -0.75 h-1). In Cx of euthyroid rats, [125I]rT3 peaked 10 min after iv injection, tissue to plasma ratio being 0.016 +/- 0.004 (SE). In thyroidectomized rats, plasma and tissue [125I]rT3 concentrations were higher than in euthyroid rats, except for the Cx that did not change. PTU caused further increases in all the tissues studied, except for the Cx and the pituitaries of thyroidectomized rats. From the effect of blocking 5'D-I with PTU or reducing its activity by making the animals hypothyroid, we concluded that 5'D-I accounts for most of the rT3 clearance from plasma. In contrast, in Cx and pituitary the levels of rT3 seem largely affected by 5'D-II activity. Since the latter results suggest that plasma rT3 does not play a major role in determining rT3 levels in these tissues, we explored the sources of rT3 in Cx using [125I]T4. The [125I]rT3 (T4) to [125I]T4 ratio remained constant at 0.03 from 1 up to 5 h after injection of [125I]T4. From plasma levels of T4 and rT3, Cx concentration was calculated to be 30 pg rT3/g Cx in euthyroid rats, more than 98% locally produced from T4 deiodination. We conclude that rT3 has a very rapid metabolism, mainly attributed to 5'D-I activity, but that 5'D-II could also play a role in certain tissues. Nearly all rT3 present in Cx is locally derived from T4.

Transfer of thyroxine from the mother to the rat fetus near term: effects on brain 3,5,3'-triiodothyronine deficiency.

It has recently been shown that thyroid hormones are transferred from the mother to the developing rat embryo early in gestation, before the onset of fetal thyroid function. We have now studied whether there is transfer of T4 from the mother to the fetus late in gestation when the fetal thyroid is impaired. Normal and thyroidectomized females were mated, given a goitrogen [methimazole (MMI)], starting before the onset of fetal thyroid function and until term, alone or together with a constant infusion of T4 (1.8 micrograms/100 g BW.day). T4 and T3 were determined by RIA in several maternal samples and in tissues from 21-day-old fetuses. The administration of MMI blocked the fetal thyroid, as assessed from the decreased thyroid concentrations of T4 and T3. The concentrations of both iodothyronines also decreased in placenta, thyroid, plasma, brain, liver, lung, and carcass of fetuses from MMI-treated dams. Infusion of T4 into such MMI-treated mothers partly avoided this decrease, and T4 levels increased in all fetal tissues to 41-57% of those in normal fetuses. In contrast to this, T4 infusion affected the concentration of T3 to varying degrees in different tissues. The T3 concentration in plasma and lung increased very little when the MMI-treated mother was infused with T4, but in the brain T3 reached concentrations comparable to those in normal fetuses. Results not only show transfer of T4 from the mother to the fetus near term, at least when the fetal thyroid is impaired, but also suggest that it might mitigate, or avoid, the adverse effects of such failure on the developing brain.

Multiple regulation of S14 gene expression during brown fat differentiation.

S14 is a gene known to be under thyroid hormone control. Its mRNA concentration is very high in lipogenic tissues, and although the precise function of the protein is still unknown, indirect data suggest its implication in triglyceride synthesis. S14 gene expression is up-regulated by thyroid hormone in liver, white adipose tissue, and lactating mammary gland. However, in brown fat, the level of this sequence is increased 3-fold in the hypothyroid animal. We have used primary cultures of brown preadipocytes differentiated to fully mature brown adipocytes to investigate the influence of cellular differentiation and hormonal stimulation on S14 gene expression. Steady state levels of S14 mRNA rose from nondetectable levels in preadipocytes to reach a maximum in fully mature adipocytes. Treatment of brown adipocytes cultures with T3 did induce S14 gene expression. This induction reflects in part a posttranscriptional stabilization of the messenger by T3. Insulin, insulin-like growth factor-I, and inositol phosphate-glycan also increase the level of S14 mRNA. Norepinephrine (NE) plays a major role in the regulation of S14 gene, and 24 h after its addition, NE elicited a 20-fold decrease in mRNA S14 concentrations. An elevated intracellular concentration of cAMP is a strong negative effector of S14 gene expression, and neither NE nor cAMP action is totally overcome by T3. As happens in vivo, glucose is a potent stimulator of S14 mRNA; however, there is a lag time of several hours before its effects can be detected. The increase in S14 gene expression with the maturation stage of the cell suggests an important role for S14 in adipocyte differentiation.

Differential effects of thyroid hormones on growth and thyrotropic hormones in rat fetuses near term.

We have studied the effects of thyroid hormone deficiency and excess on GH and TSH economy in the rat fetus near term. Pregnant rats were either left untreated (C group) or treated with methimazole to block thyroid function and infused with placebo, T4, T3, or both, until 21 days of gestation. Two experiments were performed: the doses (per 100 g body wt/day) of T4 ranging from 2.4-21.6 micrograms, those of T3 from 1.5-13.5 micrograms, with groups on 2.4 micrograms T4 + 1.5 micrograms T3. Fetal plasma T4 levels varied between 6-160% of C values and T3 values between 52-770%. Both plasma and pituitary GH decreased in hypothyroid fetuses from methimazole dams, and their plasma TSH was elevated. When T4 and/or T3 were infused, plasma and pituitary GH increased as a function of fetal plasma T4 and T3, reaching normal values when plasma T3 levels became normal, then increasing further. The effects on GH economy were related to the plasma T3 level, with no appreciable difference if T3 had been infused or derived from T4. In contrast, the elevated plasma TSH of the hypothyroid fetus decreased toward normal values when fetal plasma levels of T4, and of T3 derived from T4, became normal, but was not affected by normal fetal plasma T3 when T3 was infused. In the absence of T4, T3 decreased plasma TSH only when infused in doses that increased fetal plasma T3 3-fold above C values or more. Thus, both GH and TSH economy are under thyroid hormone control in rat fetuses near term. Similarities and differences with respect to regulation in adult rats cannot, however, be attributed exclusively to differences in fetal somatotrophs and thyrotrophs, because of the possibility that control is exerted at regulatory sites which are unique to the fetus.

The rat placenta and the transfer of thyroid hormones from the mother to the fetus. Effects of maternal thyroid status.

We have studied the effects of maternal thyroid status on the effectiveness of the rat placenta near term as a barrier for the transfer of T4 and T3 to the fetus. Dams were given methimazole to minimize the fetal contribution to the T4 and T3 pools, so that the iodothyronines found in the conceptus are ultimately of maternal origin. The dams were infused with saline, or with T4 or T3 at doses ranging from 2.3-27.8 nmol T4 and from 0.77-20.7 nmol T3/100 g BW per day. A group of normal pregnant dams (C) was included. At 21 days of gestation T4, T3, and rT3 were measured by RIA in maternal and fetal plasma, and in maternal and fetal sides of the placenta. The total fetal extrathyroidal T4 and T3 pools were also determined. The dose-related changes in T4, T3, and rT3 levels in the placenta confirm the presence of both inner and outer ring iodothyronine deiodinase activities, and suggest increasing accumulation of the iodothyronines. Despite this, fetal extrathyroidal T4 and T3 increase progressively in T4-infused groups as a function of maternal circulating T4 levels. Fetal extrathyroidal T3 increases progressively in T3-infused groups as a function of maternal plasma T3. There was no evidence that the net maternal contribution of T4 or T3 would be proportionally less when the maternal pools became very high. It was concluded that the rat placenta is only a limited barrier for the transfer of T4 and T3 to the fetus.